










A**B****C****D****E****F****G**

Supplementary Figure 1: The predicted effects of UA and SP600125 alone and in combination on viability and proliferation in the following cell lines: (A) H1437 non-small cell lung carcinoma, (B) HT29 colon adenocarcinoma, (C) H292 lung carcinoma, (D) H1155 non-small cell lung carcinoma, (E) OPM2 multiple myeloma, (F) IM9 multiple myeloma, and (G) MDAMB231 breast adenocarcinoma. The drugs concentrations used individually and in combination for all cell lines in the predictive simulation studies were set as the IC30 viability concentration for HCT116 cells.



Supplementary Figure 2: Dose variation experimental studies of SP600125 and UA in HCT116 cells. HCT116 cells were treated with indicated doses of UA and SP600125 either alone or in combination for 48 hours. Viability was assayed by the MTT assay. Bars represent the mean of 3 independent experiments. Error bars SEM.



Supplementary Figure 3: The effect of 7.5 μ M UA and 10 μ M SP600125, alone and in combination, on biomarkers of proliferation and apoptosis by Western blot in OPM2 (A) and fibroblast (B) cells. The following biomarkers were assessed: cyclin D1, phospho-c-Jun (Ser73), c-Jun and CASP3. Supplementary figures 3A and B are representative images of 3 independent experiments.